BrainsWay Accelerates International Expansion in India

Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS

BURLINGTON, Mass. and JERUSALEM, July 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expanded market penetration of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology in India. After the most recent in a series of successive multisystem orders, Asha Neuromodulation Clinics (ANC) and its affiliates will own 25 Deep TMS systems, substantially increasing access to BrainsWay’s patented technology for mental health patients suffering from a range of conditions including depression, obsessive-compulsive disorder (OCD), and smoking addiction.

“We are pleased that our unique form of therapy is gaining real traction in India,” said Hadar Levy, Chief Executive Officer of BrainsWay. “This is further proof of BrainsWay’s strategic commitment to expanding its international footprint, and allows us the ability to make a true difference in the lives of patients in the world’s most populous country. We are proud to partner with the ANC team in making this shared vision a reality.”

“At ANC, we understand the challenges of leading a fast-paced life and the need for better outcomes in mental health care delivery," said Dr. M.S. Reddy, Director of ANC. "That is why we are working with BrainsWay to offer the most advanced therapeutic solution available in the industry throughout the country, including at our new flagship clinic in Gachibowli, as well as at Asha Hospitals in Hyderabad, Bengaluru, Vizag, Mysuru, Vijayawada, Guntur, Chandigarh, and New Delhi.”

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.